MK-7762 is an orally active xazolidinone compound with antitubercular activity. MK-7762 inhibits MAO-B and mammalian mitochondrial protein synthesis. MK-7762 reduces lung bacterial burden in BALB/c mouse models of acute and chronic tuberculosis infection, penetrates caseous necrotic lung lesions in C3HeB/FeJ mice, and maintains concentrations above unbound MIC in lesion compartments. MK-7762 can be used for the research of tuberculosis.

MK-0489 is an orally active, highly effective, and selective MC4R agonist. MK-0489 exhibits a strong binding affinity (IC50 = 13 nM) and functional agonist activity (EC50 = 4.6 nM) at human MC4R. MK-0489 shows functional activity of 22 nM (EC50) on mouse MC4R and 1.7 μM (EC50) on mouse MC3R. MK-0489 can be used for the study of obesity.

MK 1256 is a highly selective and orally active inhibitor of tissue protease K (Cat K) with an IC50 of 0.62 nM. MK 1256 shows extremely high selectivity towards other tissue proteases (all > 1100 times), with only a slightly lower selectivity for tissue protease F (Cat F) (110 times). MK 1256 exhibits strong anti-bone resorption activity in the osteoporosis model of rhesus monkeys with ovariectomy. MK 1256 can be used for research on osteoporosis.

Mitoflaxone (flavoneacetic acid) is a synthetic flavonoid compound with vascular targeting properties. Mitoflaxone exerts anti-proliferative effects on endothelial cells through a superoxide-dependent mechanism, this effect leads to changes in the permeability of tumor blood vessels, thereby exerting anti-tumor effects[1][2].

m-Iodobenzylguanidine (Iobenguane) is a ligand with high affinity against norepinephrine transporter (NET). m-Iodobenzylguanidine is used as an imaging agent in the diagnostic imaging and radionuclide studies of neuroendocrine tumors, such as neuroblastoma, pheochromocytoma and carcinoid tumor.

Minaxolone is a water-soluble steroid anesthetic agent.

MINA53-IN-1 is a selective MINA53 inhibitor with an IC50 of 1.5 μM. MINA53-IN-1 induces DNA damage, cell cycle arrest and apoptosis in tumor cells. MINA53-IN-1 can be used for cancer research.

MiADMSA (Monoisoamyl meso-2,3-dimercaptosuccinic acid) is an orally active thiol chelator that can effectively remove heavy metals such as arsenic and lead from the body of animals. Arsenic binds with two vicinal sulfhydryl groups available in MiADMSA leading to marked reduction in body arsenic burden and also marked reduction in various oxidative stress parameters and antioxidant enzymes like-ROS, nitrite, TBARS, GSH, SOD and catalase. MiADMSA attenuates urinary bladder carcinogenesis, protects against oxidative stress, ameliorates copper-induced histopathology, reverses neurotoxicity, and is safe in animals. MiADMSA can be used in studies of bladder cancer, arsenic, and lead-induced developmental neurotoxicity.

mGluR7 antagonist-2 (compound 1) is a potent and selective metabotropic glutamate receptor 7 (mGluR7) allosteric antagonist (IC50 = 20 nM). mGluR7 antagonist-2 shows high selectivity over other mGluRs (mGluR1/2/3/4/5/6/8).

MGAT2-IN-7 (compound 27Q) is a substituted benzenesulfonamide compound and also a monoacylglycerol acyltransferase 2 (MGAT2) inhibitor. MGAT2-IN-7 is used for research on obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

MG16 is a prodrug of 10-Methoxycamptothecin. MG16 downregulates CDK6 and upregulates ASK1. MG16 induces cell cycle arrest and Apoptosis. MG16 exhibits anticancer activity against Lewis lung carcinoma, small cell lung cancer, and non-small cell lung cancer.

MeV-IN-1 (OX-1) is an inhibitor of specific specific Measles virus (MeV) entry with an IC50 of 100 M. MeV-IN-1 has an IC50 of 55 M against live MeV-Edm. MeV-IN-1 efficiently suppresses the formation of infectious centers. MeV-IN-1 exhibits negligible cytotoxicity. MeV-IN-1 potently suppresses R18 redistribution in MV-H- and MV-F-expressing cells, preventing membrane merging.

METTL3-IN-13 is a METTL3 inhibitor. METTL3-IN-13 is applicable to the research of multiple cancers such as hypopharyngeal squamous cell carcinoma and non-small cell lung cancer.

METTL3-IN-11 is an excellent, selective METTL3 inhibitor (IC50 = 45.31 nM). METTL3-IN-11 exhibits high selectivity towards METTL3 compared to DNMT1, EZH1, MLL1, and PRMT1. METTL3-IN-11 reduces the m6A level of total RNA in MOLM-13 and SKOV3 cells, induces cell apoptosis, and inhibits cell migration. METTL3-IN-11 can reduce the expression of m6A downstream target genes (c-MYC and BCL2). METTL3-IN-11 can be used for the study of ovarian cancer and acute myeloid leukemia.

Methyl threo-12,13-dihydroxy-9(Z)-octadecenoate is a lipid.

Methyl linolenate-13C17 is an isotope-labeled fatty acid ester.

Methyl 8(Z),11(Z),14(Z),17(Z),20(Z)-tricosapentaenoate is an unsaturated fatty acid methyl ester (FAME)。

Methyl 7(E)-nonadecenoate is an unsaturated fatty acid methyl ester (FAME)。

Methyl 6(Z),9(Z),12(Z),15(Z),18(Z)-tetracosapentaenoate is an unsaturated fatty acid methyl ester (FAME)。

Methyl 5-aminovalerate hydrochloride is a PROTAC linker that can be used in the synthesis of PROTACs.

Methyl 3-chlorobicyclo[1.1.1]pentane-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

Methyl 16(Z)-pentacosenoate is a fatty ester.

Methyl 10(Z),13(Z),16(Z)-docosatrienoate is an unsaturated fatty acid methyl ester (FAME)。

Methoctramine is a potent and cardioselectivity antagonist of M2 muscarinic receptor. Methoctramine can inhibit Muscarine-induced bradycardia in vivo. Methoctramine can be used in the study of cardiovascular diseases.

Methiocarb (Mercaptodimethur) is an orally active carbamate insecticide. Methiocarb exerts dose-dependent toxic effects on onions. In addition to inhibiting acetylcholinesterase to induce cholinergic excitation, Methiocarb can induce lipid peroxidation in liver, kidney, brain and testicular tissues and alter reduced glutathione levels by generating ROS. Methiocarb can be used for agricultural pest control and research on oxidative stress-related cellular damage in mammals.

Methetoin is an anticonvulsant.

Mer/c-Met-IN-1 is a potent Mer/c-met dual inhibitor with IC50 values of 1 and 19 nM. Mer/c-Met-IN-1 can inhibit cancer cells proliferation, migration and induce apoptosis. Mer/c-Met-IN-1 can be used for the research of cancer, such as colon cancer.

Menin-MLL-IN-37 is an orally active Menin-MLL protein complex inhibitor with an IC50 of 820.50 nM. Menin-MLL-IN-37 disrupts the interaction between menin and MLL proteins. Menin-MLL-IN-37 induces differentiation of acute myeloid leukemia cells and selectively inhibits the proliferation of MLL-rearranged and DNMT3A/NPM1-mutant leukemia cells. Menin-MLL-IN-37 can be used for the research of acute myeloid leukemia (AML).

Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.

Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC50 value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.